title: Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism.
abstract: Application of the widely used immunosuppressant (ISS) cyclosporine (CsA) is severely limited by a number of serious side-effects such as kidney and neurotoxicity. As we have shown before, CsA exhibits metabolic toxicity in brain-models. The macrolide ISSs sirolimus (SRL) and everolimus (RAD) are capable of modulating these CsA-induced effects. It was our aim to study the age-dependent metabolic changes in the rat brain after ISS-treatment and the possible role of the blood-brain-barrier in modulation of CsA metabolic toxicity. Young and adult rats were treated orally with one ISS alone or in combination with CsA for six days. Metabolic changes were assessed by nuclear magnetic resonance (NMR) spectroscopy of brain extracts as toxicodynamic endpoints. Brain P-glycoprotein (P-gp) and ISS concentrations were determined as pharmacokinetic endpoints. Young rats were more susceptible to CsA-induced inhibition of the Krebs cycle (glutamate: 78% of controls, glutamine: 82%, GABA: 71% in young vs. 85%, 89%, 92% in adult rats). Increased glycolysis after CsA-treatment was sufficient to maintain the energy state at control levels in adult brains, but not in the young rat brains (phosphocreatine: 35%). Tissue concentrations of CsA and SRL within the brain of young rats were three-fold higher, while concentrations of P-gp were three-fold higher in adult rat brains. Our results suggest that age-dependent differences in the blood-brain barrier led to increased ISS brain concentrations and hence inhibition of brain energy metabolism.
authors.affiliation: Max Planck Institute for Biological Cybernetics, High-Field Magnetic Resonance Center, Tübingen, Germany. Sven.Gottschalk@tuebingen.mpg.de
authors.forename: Sven
authors.initials: S
authors.lastname: Gottschalk
authors.forename: Carolyn L
authors.initials: CL
authors.lastname: Cummins
authors.forename: Dieter
authors.initials: D
authors.lastname: Leibfritz
authors.forename: Uwe
authors.initials: U
authors.lastname: Christians
authors.forename: Leslie Z
authors.initials: LZ
authors.lastname: Benet
authors.forename: Natalie J
authors.initials: NJ
authors.lastname: Serkova
mesh_terms: D000367:Age Factors; D000375:Aging / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000276:immunology; D001921:Brain / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism*; D016572:Cyclosporine / Q000633:toxicity*; D004734:Energy Metabolism / Q000187:drug effects / Q000276:immunology; D000068338:Everolimus; D005260:Female; D007166:Immunosuppressive Agents / Q000633:toxicity*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012727:Sex Characteristics; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000633:toxicity*
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000068338:Everolimus; D020123:Sirolimus